Etropal ADXBUL:ETR 50 ROE % is 3.57% as of Dec. 2025, which is 950% above its 10-year median of 0.34. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.56 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Etropal AD ranks better than 53.95% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Etropal AD's annualized net income for the quarter that ended in Dec. 2025 was €0.16 Mil. Etropal AD's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €4.37 Mil. Therefore, Etropal AD's annualized ROE % for the quarter that ended in Dec. 2025 was 3.57%.
The historical rank and industry rank for Etropal AD's ROE % or its related term are showing as below:
XBUL:ETR'
s ROE % Range Over the Past 10 Years
Min: -48.66 Med: 0.34 Max: 3.56
Current: 3.56
During the past 13 years, Etropal AD's highest ROE % was 3.56%. The lowest was -48.66%. And the median was 0.34%.
XBUL:ETR's ROE % is ranked better than 53.95% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs XBUL:ETR: 3.56
Etropal AD (XBUL:ETR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is one times the annual (Dec. 2025) net income data. The Revenue data used here is one times the annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Etropal AD ROE % Related Terms
Etropal AD ROE % Historical Data
* Premium members only.
The historical data trend for Etropal AD's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Etropal AD's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's ROE % distribution charts can be found below:
* The bar in red indicates where Etropal AD's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Etropal AD (XBUL:ETR) has a ROE % of 3.57% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Etropal AD and its competitors. This is 950% above median its historical median of 0.34. According to the industry distribution chart, Etropal AD ranks #367 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 46%.
Is Etropal AD's ROE % too high?
Etropal AD's current ROE % of 3.57% is 950% above median its 10-year median of 0.34. The Medical Devices & Instruments industry median ROE % is 2.40. Etropal AD's value of 3.57% is 48.8% above this industry median. Based on the distribution chart, Etropal AD ranks #367 out of 797 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #367 out of 797 companies for ROE %. This puts Etropal AD in the upper half of its industry. The industry median ROE % is 2.40. Etropal AD's value of 3.57% is 48.8% above this benchmark. While the company's 10-year median is 0.34 vs. the industry median of 2.40, Etropal AD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current ROE % of 3.57% is 48.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current ROE % is 3.57%, which is 950% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.56, compared to a current price of €2.52 — trading 70.6% below its estimated fair value. The current ROE % is 3.57%, which is 950% above median its 10-year median of 0.34 and 48.8% above the Medical Devices & Instruments industry median of 2.40. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current ROE % is 3.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.52 is trading 70.6% below its estimated GF Value™ of €8.56.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
ROE %: 3.57% (950% above median its 10-year median of 0.34)
GF Value™: €8.56 vs. price of €2.52 (70.6% below fair value)
Industry Position: 48.8% above the Medical Devices & Instruments median (#367 of 797)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
